EW UBS upgraded Edwards Lifesciences to Buy from Neutral with a price target of $110, up from $90, after assuming coverage of the name. Edwa

EW UBS upgraded Edwards Lifesciences to Buy from Neutral with a price target of $110, up from $90, after assuming coverage of the name. Edwards Lifesciences is entering a new growth phase driven by continued TAVR adoption, expansion into structural heart therapies, and a broader heart failure ecosystem, with shares undervaluing the durability of its innovation pipeline and potential for earnings growth and multiple expansion, the analyst tells investors in a research note.